Literature DB >> 14699428

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.

R Alonso1, G Griebel, G Pavone, J Stemmelin, G Le Fur, P Soubrié.   

Abstract

Repeated exposure to stress is known to induce structural remodelling and reduction of neurogenesis in the dentate gyrus. Corticotrophin-releasing factor (CRF) and vasopressin (AVP) are key regulators of the stress response via activation of CRF(1) and V(1b) receptors, respectively. The blockade of these receptors has been proposed as an innovative approach for the treatment of affective disorders. The present study aimed at determining whether the CRF(1) receptor antagonist SSR125543A, the V(1b) receptor antagonist SSR149415, and the clinically effective antidepressant fluoxetine may influence newborn cell proliferation and differentiation in the dentate gyrus of mice subjected to the chronic mild stress (CMS) procedure, a model of depression with predictive validity. Repeated administration of SSR125543A (30 mg/kg i.p.), SSR149415 (30 mg/kg i.p.), and fluoxetine (10 mg/kg i.p.) for 28 days, starting 3 weeks after the beginning of the stress procedure, significantly reversed the reduction of cell proliferation produced by CMS, an effect which was paralleled by a marked improvement of the physical state of the coat of stressed mice. Moreover, mice subjected to stress exhibited a 53% reduction of granule cell neurogenesis 30 days after the end of the 7-week stress period, an effect which was prevented by all drug treatments. Collectively, these results point to an important role of CRF and AVP in the regulation of dentate neurogenesis, and suggest that CRF(1) and V(1b) receptor antagonists may affect plasticity changes in the hippocampal formation, as do clinically effective antidepressants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14699428     DOI: 10.1038/sj.mp.4001464

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  71 in total

Review 1.  Depression, antidepressants, and neurogenesis: a critical reappraisal.

Authors:  Nicola D Hanson; Michael J Owens; Charles B Nemeroff
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 3.  Regulation of Adult Neurogenesis and Plasticity by (Early) Stress, Glucocorticoids, and Inflammation.

Authors:  Paul J Lucassen; Charlotte A Oomen; Eva F G Naninck; Carlos P Fitzsimons; Anne-Marie van Dam; Boldizsár Czeh; Aniko Korosi
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-01       Impact factor: 10.005

Review 4.  Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations.

Authors:  Eleni Paizanis; Sabah Kelaï; Thibault Renoir; Michel Hamon; Laurence Lanfumey
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

Review 5.  Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology.

Authors:  Darrick T Balu; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2008-08-19       Impact factor: 8.989

6.  Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.

Authors:  Nicola D Hanson; Charles B Nemeroff; Michael J Owens
Journal:  J Pharmacol Exp Ther       Date:  2011-01-10       Impact factor: 4.030

Review 7.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

8.  Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.

Authors:  I Muñoz-Cobo; M M Erburu; C Zwergel; R Cirilli; A Mai; S Valente; E Puerta; Rosa M Tordera
Journal:  Psychopharmacology (Berl)       Date:  2018-08-08       Impact factor: 4.530

9.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

Review 10.  [Neurogenesis. Relevance for pathophysiology and pharmacotherapy of psychiatric diseases].

Authors:  J Thome; A J Eisch
Journal:  Nervenarzt       Date:  2005-01       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.